Vaishali Pharma Limited — Capital/Financing Update 2021

Jan 14, 2021

==> picture [140 x 47] intentionally omitted <==

==> picture [53 x 44] intentionally omitted <==

==> picture [67 x 67] intentionally omitted <==

Vaishali Pharma Limited

CIN: L52310MH2008PLC181632

==> picture [271 x 43] intentionally omitted <==

PRESS RELEASE

THE COMPANY HAS RECEIVED YET ANOTHER BULK ORDER WORTH INR 320 MILLION OF PPE KITS

Mumbai, January 14, 2021 : Vaishali Pharma Limited (NSE:- VAISHALI), a Mumbai based Company, engaged in supply of pharmaceutical products to corporates, hospitals and retails stores in all SKUs required. Our products have made its grasp on the overseas market and getting an excellent feedback worldwide. The Company is showing consistent agility and innovation by meeting the needs of its customers in both Domestic and International markets.

We are pleased to inform our shareholders that after Implementation of planned marketing strategies along with firm efforts, the Company is among the fastest growing organizations in the Pharmaceutical Industry for the supply of Medical Products to Domestic & International Market, and with such the Company has received yet another Bulk Order worth INR 320 Million for the supply of the Pharma and Consumable Products such as PPE Kits which forms a part of COVID-19 Medical Kit. The Company has established a good reputation and is expecting approvals in International Markets and many more opportunities in near future.

The Personal Protective Equipment (PPE) refers to the protective clothing, helmets, gloves, face shields, goggles, facemasks and / or respirators or other equipment designed to protect the wearer from injury or the spread of infection or illness. The Disposable Coverall suits are one piece fitting for ease of movement, with sleeves, full leggings and often a hood to cover the head. The gloves help to protect when directly handling potentially infectious materials or contaminated surfaces. Facemasks help protect the nose and mouth from splattered of body fluids and other air borne infections before inhalation. A face shield provides splatter protection to facial skin, eyes, nose, and mouth. Shoe and head covers provide a barrier against possible exposure within a contaminated environment.

The range of different Covid-19 medical products such as hand sanitizer, 3 ply mask, N95 Masks, KN95 Masks, IR Thermometer, Oximeter, Face Shield, Sanitizer Stand, Sanitizer Dispenser, goggles, gloves etc. The multivitamin sprays such as `Vipramultivita spray, Vipravita D3 spray, Viprafolic A spray, Vipravta spray. The Immunity Booster such as Vipravita C supplements in different variants viz. – Vitamin C chewable tablets, Vitamin C effervescent tablets and Vitamin C with Zinc combo to fight against COVID -19 pandemic.

Mr. Atul Arvind Vasani, Chairman and Managing Director of the Company says that: “ Adapting quickly to the ever-evolving demands, the Company has emerged as one of the fastest growing organization in the Pharmaceutical Industry for the supply of Medical Products to Domestic & International Market, and in this Covid-19 Pandemic, we are trying to reach maximum people with quality medical products at affordable price.

The Company is expecting a tremendous growth and a better quarterly performance along with many more opportunities from the Domestic as well as International Market in near future.”

ABOUT VAISHALI PHARMA LIMITED:

Vaishali Pharma Limited is a globally well trusted brand with high quality products, accepted by companies across the globe. The Company is amongst the leading players in the supply of pharma products – Bulk Drugs / APIs, Formulations, Surgical Products, Veterinary supplements, Herbal & Nutraceutical products, with a well-established brand known for its high-quality products & services amongst various clients

Vaishali Pharma Limited CIN: L52310MH2008PLC181632

==> picture [271 x 43] intentionally omitted <==

globally. The company has over 150+ formulation brands marketed in multiple countries; of which dossier is in CTD format along with its respective bioequivalence. The company has built a robust pipeline of around 250 Dossiers. The Company’s synergistic collaboration with WHO-GMP manufacturing facilities is backed by an excellent rapport with clients.

Strong commitment of providing quality products is backed by in-depth industry knowledge, well qualified team of professionals, as well as hi-tech and advanced infrastructure. Resulting in creating mutually beneficial associations for all the clients.

The Company has also establish good partners in amongst 32 countries with over 150+ brands marketed, which is a rare possibility for any company to achieve. Further widening our reach overseas, the Company exports to countries such as Afghanistan, Angola, Armenia, Burkina - Faso, Cambodia, Cameroon, Costa Rica, D. R. Congo, Dubai, Egypt, Ethiopia, Gambia, Guinea - Bissau, Guinea - Conakry, Iraq, Kenya, Lebanon, Madagascar, . Myanmar, Nicaragua, Nigeria, Oman, Papua New Guinea, Philippines, Russia, Sri Lanka, Tajikistan, Tanzania, USA, Vietnam, Yemen, Zimbabwe.

At Vaishali Pharma, we are working tirelessly to make available health improving pharmaceutical products affordable and accessible to all. Looking beyond this immediate term, the upcoming half year shall present more good opportunities for the Company and we shall continue to perform better than the previous half year.

Adhering to high quality standards is not an accident but our habit. Passionate to be the best, we take pride in what we do and strive to deliver products with zero defects. One can count upon us for quality pharmaceutical and healthcare products.

For more details please visit:www.vaishalipharma.com	For more details please visit:www.vaishalipharma.com	For more details please visit:www.vaishalipharma.com
For anyInvestor Relationsquery,please contact:
	Mr. Akshay Jharkhandi	Mr. Ratnesh Singh
	Company Secretary	Chief Financial Officer
	Email: cs@vaishalipharma.com	Email: investor@vaishalipharma.com

Note : Certain statements in this document may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like regulatory changes, local political or economic developments, and many other factors that could cause our actual results to differ materially from those contemplated by the relevant forward-looking statements. Further, past performance is not necessarily indicative of future results. Given these risks, uncertainties and other risk factors, viewers are cautioned not to place undue reliance on these forward-looking statements. The Company will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.